Giuseppe Pinto

Dr. Giuseppe Pinto

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
RSRoberto Spoladore
Roberto Spoladore
GPGiuseppe Pinto
Giuseppe Pinto
FDFrancesca Daus
Francesca Daus
SPSara Pezzini
Sara Pezzini
DKDamianos Kolios
Damianos Kolios
GFGabriele Fragasso
Gabriele Fragasso
In dilated cardiomyopathy (DCM), where the heart muscle becomes stretched and thin, heart failure (HF) occurs, and the cardiomyocytes suffer from an energetic inefficiency caused by an abnormal cardiac metabolism. Although underappreciated as a potential therapeutic target, the optimal metabolic milieu of a failing heart is still largely unknown and subject to debate. Because glucose naturally has a lower P/O ratio (the ATP yield per oxygen atom), the previous studies using this strategy to increase glucose oxidation have produced some intriguing findings. In reality, the vast majority of small-scale pilot trials using trimetazidine, ranolazine, perhexiline, and etomoxir have demonstrated enhanced left ventricular (LV) function and, in some circumstances, myocardial energetics in chronic ischemic and non-ischemic HF with a reduced ejection fraction (EF). However, for unidentified reasons, none of these drugs has ever been tested in a clinical trial of sufficient size. Other pilot studies came to the conclusion that because the heart in severe dilated cardiomyopathy appears to be metabolically flexible and not limited by oxygen, the current rationale for increasing glucose oxidation as a therapeutic target is contradicted and increasing fatty acid oxidation is supported. As a result, treating metabolic dysfunction in HF may benefit from raising ketone body levels. Interestingly, treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i) improves cardiac function and outcomes in HF patients with or without type 2 diabetes mellitus (T2DM) through a variety of pleiotropic effects, such as elevated ketone body levels. The improvement in overall cardiac function seen in patients receiving SGLT2i could be explained by this increase, which appears to be a reflection of an adaptive process that optimizes cardiac energy metabolism. This review aims to identify the best metabolic therapeutic approach for DCM patients, to examine the drugs that directly affect cardiac metabolism, and to outline all the potential ancillary metabolic effects of the guideline-directed medical therapy. In addition, a special focus is placed on SGLT2i, which were first studied and prescribed to diabetic patients before being successfully incorporated into the pharmacological arsenal for HF patients.

30 October 2024 in The American Journal of Cardiology
Verified
Journal Article
Closed access
GPGiuseppe Pinto
Giuseppe Pinto
MCMauro Chiarito
Mauro Chiarito
TPTania Puscas
Tania Puscas
ABAnne Bacher
Anne Bacher
EDErwan Donal
Erwan Donal
AHAlbert Hagège
Albert Hagège

18 March 2020 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
GPGiuseppe Pinto
Giuseppe Pinto
GFGabriele Fragasso
Gabriele Fragasso
MGMarco Gemma
Marco Gemma
LBLetizia Bertoldi
Letizia Bertoldi
ASAnna Salerno
Anna Salerno
MCMauro Carlino
Mauro Carlino

3 July 2022 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
GPGiuseppe Pinto
Giuseppe Pinto
GFGabriele Fragasso
Gabriele Fragasso
Recommended therapy for calcific degenerative aortic stenosis (AS) is still aortic valve replacement (AVR), either transcatheter or surgical, since no conclusive efficacy has been determined in slowing the degenerative process by medical therapy. This paper offers a brief overview of molecular mechanisms leading to calcification of aortic valve. It is then focused on potential markers of disease progression, as observed in many observational studies. Finally it provides a comprehensive review of drugs already tested in in vitro and human studies in order to slow aortic valve stenosis process. Despite research providing numerous molecular pathways underlying the calcification process, further efforts must be made to understand risk factors linked to disease progression. Some existing treatments that have already provided survival benefits in many features of cardiovascular diseases are currently being tested with promising results. In the near future new drugs acting on specific pathways by techniques such as monoclonal antibodies and RNA interference, are expected to provide better medical solutions for this ever growing number of patients.

1 May 2019 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
GPGiuseppe Pinto
Giuseppe Pinto
LTLara Tondi
Lara Tondi
MGMarco Gemma
Marco Gemma
AMAlessandro De Marco
Alessandro De Marco
CSCarmen Silipigni
Carmen Silipigni
GFGabriele Fragasso
Gabriele Fragasso
Objective: International guidelines recommend the introduction of sacubitril/valsartan (Entresto) in patients with heart failure (HF) and reduced ejection fraction (EF), who remain symptomatic, despite optimal uptitrated therapy. The purpose of the following analysis is to verify the real-life eligibility for sacubitril/valsartan in a population of patients suffering from chronic HF, regularly monitored in a single HF clinic and treated according to guideline-directed medical therapy (GDMT). Methods: From a total of 1070 patients regularly monitored in our HF Clinic between January 2011 and September 2017, the clinical records of 224 patients with HF and reduced EF on optimized GDMT were retrospectively analyzed. Results: Of 224 analyzed patients, 75 improved their EF or were asymptomatic after uptitration of GDMT during follow-up; 50 were not on angiotensin-converting enzyme inhibitor or angiotensin receptor blocker for different reasons; 13 patients had systolic blood pressure ≤100 mm Hg, so they were not eligible for sacubitril/valsartan introduction. The remaining patients were still symptomatic (NYHA ≥2), and therefore, sacubitril/valsartan introduction was indicated in these 86 patients (38.4%) of 224 enrolled. Conclusion: In patients with HF and reduced EF, where GDMT is appropriately achieved, indication to sacubitril/valsartan treatment is around 38%.

24 December 2024 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
GMGuido Del Monaco
Guido Del Monaco
FAFrancesco Amata
Francesco Amata
VBVincenzo Battaglia
Vincenzo Battaglia
CPCristina Panico
Cristina Panico
Gerolama CondorelliGerolama Condorelli
Gerolama Condorelli
GPGiuseppe Pinto
Giuseppe Pinto
Cardiomyopathies, historically regarded as rare, are increasingly recognized due to advances in imaging diagnostics and heightened clinical focus. These conditions, characterized by structural and functional abnormalities of the myocardium, pose significant challenges in both chronic and acute patient management. A thorough understanding of the hemodynamic properties, specifically the pressure-volume relationships, is essential. These relationships provide insights into cardiac function, including ventricular compliance, contractility, and overall cardiovascular performance. Despite their potential utility, pressure-volume curves are underutilized in clinical settings due to the invasive nature of traditional measurement techniques. Recognizing the dynamic nature of cardiomyopathies, with possible transitions between phenotypes, underscores the importance of continuous monitoring and adaptive therapeutic strategies. Enhanced hemodynamic evaluation can facilitate tailored treatment, potentially improving outcomes for patients with these complex cardiac conditions.